VKH
AIMT

Virtu KCG Holdings’s Aimmune Therapeutics AIMT Stock Holding History

Virtu KCG Holdings’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-14,851
Closed -$304K – 3992
2016
Q4 		$304K Buy
14,851
+4,419
+42% +$90.3K 0.01% 2083
2016
Q3 		$156K Buy
+10,432
New +$141K ﹤0.01% 2486

Other funds holding AIMT

FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Virtu KCG Holdings's AIMT Position: Q1 2017 in Review

Virtu KCG Holdings sold out of Aimmune Therapeutics (AIMT) in Q1 2017, closing a stake of 14,851 shares — an estimated $304K sold.

Virtu KCG Holdings first reported a position in AIMT in Q3 2016 and held it in 2 quarters. The position peaked at $304K in Q4 2016. 90 funds tracked by Wall St. Rank hold AIMT as of Q1 2017.

  • Virtu KCG Holdings reported no remaining Aimmune Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Virtu KCG Holdings sold 14,851 Aimmune Therapeutics shares in Q1 2017, an estimated $304K.
  • Virtu KCG Holdings first reported a position in Aimmune Therapeutics in Q3 2016 and held it in 2 quarters.
  • Virtu KCG Holdings's Aimmune Therapeutics position peaked at $304K in Q4 2016.
  • 90 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2017.

Based on Virtu KCG Holdings's 13F filing for Q1 2017, filed 12 May 2017.